RU93004918A - Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции - Google Patents

Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции

Info

Publication number
RU93004918A
RU93004918A RU93004918/14A RU93004918A RU93004918A RU 93004918 A RU93004918 A RU 93004918A RU 93004918/14 A RU93004918/14 A RU 93004918/14A RU 93004918 A RU93004918 A RU 93004918A RU 93004918 A RU93004918 A RU 93004918A
Authority
RU
Russia
Prior art keywords
conjugates
target cells
superantigen
pharmomo
lizing
Prior art date
Application number
RU93004918/14A
Other languages
English (en)
Other versions
RU2125889C1 (ru
Inventor
Т.Калланд
Г.Хедлунд
П.Ландо
Е.Окерблом
Original Assignee
Каби Фармация А.Б.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002479A external-priority patent/SE9002479D0/xx
Priority claimed from SE9002484A external-priority patent/SE9002484L/xx
Application filed by Каби Фармация А.Б. filed Critical Каби Фармация А.Б.
Priority claimed from PCT/SE1991/000496 external-priority patent/WO1992001470A1/en
Publication of RU93004918A publication Critical patent/RU93004918A/ru
Application granted granted Critical
Publication of RU2125889C1 publication Critical patent/RU2125889C1/ru

Links

Claims (1)

  1. Новые растворимые конъюгаты антитела содержат антитело, связанное со структурой, узнаваемой Т-клетками и способной направлять Т-клетки на лизирование клетки - мишени, узнаваемой антителом. Конъюгат характеризуется тем, что указанная структура представляет собой суперантиген. Одним из наиболее важных аспектов является лизирование клеток-мишеней, в результате которого клетки-мишени вступают в контакт с эффективным для лизирования клеток-мишеней количеством конъюгата. Способ лизирования эффективен при лечении рака, аутоиммунных заболеваний, заражений паразитами и инфекций, вызванных грибками, вирусами и бактериями. Важен также такой аспект, как синтез конъюгата, фармацевтические композиции и их приготовление.
RU93004918A 1990-07-20 1991-07-16 Растворимый конъюгат антитела, способ лечения онкологического заболевания, фармацевтическая композиция RU2125889C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE9002479A SE9002479D0 (sv) 1990-07-20 1990-07-20 Antibody conjugates
SE9002484A SE9002484L (sv) 1990-07-20 1990-07-20 Nya substituerade polyetrar
SE0002484-5 1990-07-20
SE9002484-5 1990-07-20
SE9002479-5 1990-07-20
PCT/SE1991/000496 WO1992001470A1 (en) 1990-07-20 1991-07-16 Target specific antibody-superantigen conjugates and their preparation

Publications (2)

Publication Number Publication Date
RU93004918A true RU93004918A (ru) 1995-05-10
RU2125889C1 RU2125889C1 (ru) 1999-02-10

Family

ID=26660818

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93004918A RU2125889C1 (ru) 1990-07-20 1991-07-16 Растворимый конъюгат антитела, способ лечения онкологического заболевания, фармацевтическая композиция

Country Status (16)

Country Link
EP (1) EP0610179B1 (ru)
JP (1) JP3334130B2 (ru)
KR (1) KR100189024B1 (ru)
AT (1) ATE144145T1 (ru)
AU (1) AU656906B2 (ru)
CA (1) CA2087164C (ru)
DE (1) DE69122777T2 (ru)
DK (1) DK0610179T3 (ru)
ES (1) ES2094231T3 (ru)
GR (1) GR3022202T3 (ru)
HK (1) HK1007955A1 (ru)
HU (1) HU218603B (ru)
LV (1) LV10201B (ru)
NO (1) NO312816B1 (ru)
RU (1) RU2125889C1 (ru)
WO (1) WO1992001470A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
GB9114399D0 (en) * 1991-07-03 1991-08-21 Ici Plc Conjugates
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DE69332948T2 (de) * 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
EP0659438A1 (en) * 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
GB9326574D0 (en) * 1993-12-31 1994-03-02 King S College London Dry power inhalers
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
ATE381948T1 (de) 1995-05-10 2008-01-15 Kyowa Hakko Kogyo Kk Cytotoxinkonjugate umfassend dipeptide
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
ATE230614T1 (de) 1998-07-13 2003-01-15 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
EP0334300A1 (en) * 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体

Similar Documents

Publication Publication Date Title
RU93004918A (ru) Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции
CA2015060A1 (en) Novel antibody delivery system for biological response modifiers
NO924088D0 (no) Antistoffer, fremgangsmaate for deres fremstilling og anvendelse derav
EA200201042A1 (ru) Способ лечения с использованием конъюгатов лиганд-иммуноген
ES2078521T3 (es) Nuevos conjugados de proteina-polication.
SE8305878L (sv) Nya azolforeningar
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
MA18942A1 (fr) Nouvelles benzophenone hydrazones,leur procede de preparation et leur application comme pesticides
DK0610179T3 (da) Målspecifikke antistof-superantigenkonjugater og fremstilling deraf
FR2336138A1 (fr) Substance pharmacologiquement active obtenue a partir de plantes appartenant a la famille des labiacees, sa preparation et ses applications
CA2434009A1 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
IT8020823A0 (it) Collettore per l'assorbimento di energia solare.
BE845529A (fr) Nouvelles 3-alkoxy-benzo-1,2,4-triazines, leur procede de preparation et leur application comme fongicides et bactericides
CS55990A3 (en) Phenylhydrazones, process of their preparation and cosmetic preparations and pharmaceuticals made therefrom
IT1148013B (it) Procedimento per ottenere preparati di tossoplasmi per la diagnosi del la tossoplasmosi e preparati cosi' ottenuti
孟繁静 et al. Isolation of zearalenone from shoot apices of overwintering winter wheat
FR2658186B1 (fr) Nouveaux sels de metaux bivalents, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
BE864992A (fr) Triazinones, leur procede de preparation et leur application en therapeutique
FR2645747B1 (fr) Nouvelles compositions pharmaceutiques, leur procede d'obtention et leur emploi en therapeutique tumorale
FR2392985A1 (fr) N-formyl-phenylhydrazones, leur preparation et leur application comme fongicides
FR2594628B1 (fr) Machine de recolte pour culture en lignes, notamment pour la vigne
RU96110272A (ru) Способ стимулирования гуморального и клеточного ответа на целевой антиген
RU94026978A (ru) Иммунотерапевтический препарат